GlobalData on MSN2d
AstraZeneca lung cancer therapy Imfinzi recommended for EU approval
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended AstraZeneca's Imfinzi ...
AstraZeneca Q4 Earnings: Revenue And EPS Beat On Higher Cancer And Respiratory Drug Sales, Faces $4.5 Million Potential Fine In China
AstraZeneca Plc (NASDAQ:AZN) reported fourth-quarter sales of $14.89 billion, up 18% year over year (+19% at constant ...
AstraZeneca’s Imfinzi recommended for approval in EU by CHMP
Imfinzi has been recommended for approval in the European Union, EU, as monotherapy for the treatment of adults with ...
AstraZeneca gains as Q4 results clear China overhang
AstraZeneca (AZN) stock rises as its Q4 results which exceeded Street forecasts address concerns over its China investigation ...
AstraZeneca continues to ‘fully cooperate’ with Chinese authorities
The company said, “In relation to the illegal drug importation allegations, in January 2025, AstraZeneca (AZN) received a Notice of Transfer to ...
PMLiVE3d
AstraZeneca’s Imfinzi recommended by CHMP to treat small cell lung cancer
The Committee for Medicinal Products for Human Use (CHMP) has recommended that the immunotherapy be approved to treat adults ...
FiercePharma7h
AstraZeneca warns of potential tax fines amid China sales slowdown, illegal drug importation probe
AstraZeneca on Thursday warned that it could be fined millions of dollars in importation tax fines as Chinese authorities ...
Investor's Business Daily on MSN1h
AstraZeneca Could Pay $4.5 Million In China Scandal. Here's Why Shares Jumped.
AstraZeneca stock rose early Thursday after the drugmaker beat fourth-quarter earnings views and delivered upbeat guidance.
Pharmaceutical Technology1h
AstraZeneca’s shares rise as it addresses China investigation
In addition to the UK investment controversy, AstraZeneca is also dealing with legal challenges in China. The company ...
AstraZeneca shares rise as China probe update reassures
AstraZeneca shares rose on Thursday after the drugmaker said it could face a fine of up to $4.5 million in China over ...
Astrazeneca's revenue soars despite China woes as it 'doesn't pay £700m tax bill'
The pharmaceutical giant's revenue jumped 21 per cent last year despite growing troubles over its presence in China, where it ...
AstraZeneca PLC: Imfinzi recommended for EU approval for LS-SCLC
Imfinzi recommended for approval in the EU by CHMP as first and only immunotherapy for limited-stage small cell lung cancer Recommendation based on ADRIATIC Phase III trial results which ...